ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older. ENBREL is indicated for ...
THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...
Phase 3 psoriatic arthritis data for ENBREL® (etanercept) announced at a national scientific meeting
SAN FRANCISCO, November 11, 2001 – Phase 3 results of ENBREL® (etanercept) studied in patients with psoriatic arthritis will be presented this week at the 65th Annual American College of Rheumatology ...
THOUSAND OAKS, Calif., and RADNOR, Penn., – Results from a study of ENBREL® (etanercept), the only fully human TNF receptor, were presented demonstrating significant inhibition in the progression of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results